Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CARGO Therapeutics, Inc. (CRGX)
NASDAQ:CRGX
RESEARCH TOOLSreports
Holding CRGX?
Track your performance easily
CRGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.14 - $33.92
Previous Close$22.36
Volume142.39K
Average Volume (3M)308.80K
Market Cap
$986.49M
Enterprise Value$571.15M
Total Cash (Recent Filing)$443.48M
Total Debt (Recent Filing)$28.14M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Aug 12, 2024EPS Estimate
-$1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.54
Shares Outstanding45,904,634
10 Day Avg. Volume151,442
30 Day Avg. Volume308,795
Standard Deviation0.19
R-Squared0.16
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.35
Price to Sales (P/S)98649.06
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue57.12K
Enterprise Value/Gross Profit1.97K
Enterprise Value/Ebitda-5.45
Forecast
1Y Price Target
$32.25Price Target Upside44.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
CARGO Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentFiri-cel's efficacy results position it as a potentially more efficacious treatment post CD19-targeted CAR-T, addressing a substantial unmet need for patients who relapse.
Financial PerformanceCargo Therapeutics ended 2Q24 with roughly $443.5M in cash and cash equivalents, providing an operational runway through 2026 and past multiple key data catalysts.
Management And StrategyCARGO's management team has significant experience in CAR-Ts, bispecifics, and B cell cancers, which increases confidence in the company’s trial design.
Bears Say
Clinical TrialsNegative clinical results with firi-cel could adversely impact the stock's performance.
Competitive LandscapeIncreased competition from other cellular therapies and bispecifics currently in clinical development could challenge market share.
Regulatory ApprovalsInability to obtain regulatory approvals in a timely manner or at all poses a significant risk.
---
Ownership Overview
31.19% Insiders
21.45% Mutual Funds
3.36% Other Institutional Investors
35.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CRGX FAQ
What was CARGO Therapeutics, Inc.’s price range in the past 12 months?
CARGO Therapeutics, Inc. lowest stock price was $13.14 and its highest was $33.92 in the past 12 months.
What is CARGO Therapeutics, Inc.’s market cap?
Currently, no data Available
When is CARGO Therapeutics, Inc.’s upcoming earnings report date?
CARGO Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2024 which is 90 days ago.
How were CARGO Therapeutics, Inc.’s earnings last quarter?
CARGO Therapeutics, Inc. released its earnings results on Mar 21, 2024. The company reported -$1.49 earnings per share for the quarter, beating the consensus estimate of -$1.621 by $0.131.
Is CARGO Therapeutics, Inc. overvalued?
According to Wall Street analysts CARGO Therapeutics, Inc.’s price is currently Undervalued.
Does CARGO Therapeutics, Inc. pay dividends?
CARGO Therapeutics, Inc. does not currently pay dividends.
What is CARGO Therapeutics, Inc.’s EPS estimate?
CARGO Therapeutics, Inc.’s EPS estimate is -$1.
How many shares outstanding does CARGO Therapeutics, Inc. have?
CARGO Therapeutics, Inc. has 45,904,633 shares outstanding.
What happened to CARGO Therapeutics, Inc.’s price movement after its last earnings report?
CARGO Therapeutics, Inc. reported an EPS of -$1.49 in its last earnings report, beating expectations of -$1.621. Following the earnings report the stock price went up 5.448%.
Which hedge fund is a major shareholder of CARGO Therapeutics, Inc.?
Among the largest hedge funds holding CARGO Therapeutics, Inc.’s share is Perceptive Advisors LLC. It holds CARGO Therapeutics, Inc.’s shares valued at 60M.
---
CARGO Therapeutics, Inc. Stock Smart Score
Company Description
CARGO Therapeutics, Inc.
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
---
CRGX Stock 12 Month Forecast
Average Price Target
$32.25
▲(44.23% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Black Diamond Therapeutics
―
Fate Therapeutics
―
Gritstone bio
―
Best Analysts Covering CRGX
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+27.43%
reiterated a buy rating 3 months ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +27.43% per trade.
---